|
Dec 13
|
Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of Directors
|
|
Dec 11
|
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting
|
|
Dec 4
|
Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting
|
|
Nov 7
|
Nurix Therapeutics to Participate in Upcoming Investor Conferences
|